Article Details

Durvalumab extends survival in limited-stage small-cell lung cancer - Healio

Retrieved on: 2024-06-04 19:42:43

Tags for this article:

Click the tags to see associated articles and topics

Durvalumab extends survival in limited-stage small-cell lung cancer - Healio. View article details on hiswai:

Summary

The article discusses the survival benefits of durvalumab in treating limited-stage small-cell lung cancer, a major focus in the biopharma industry. The key biopharmaceutical companies involved in related research and development include Amgen, G1 Therapeutics, Novartis, Roche, and Eli Lilly and Company.

Article found on: www.healio.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up